The expanded Covishield dose gap becomes stronger, showing research

New Delhi, November 14, 2021:

An extended gap of at least 12 weeks between two doses of Covishield provides a better immune response among the majority of vaccinated Indians, facilitating the immediate need for booster shots. The official assessment of the actual data from the seroprevalence study is shown. Citing the findings, experts also ruled out the possibility of reducing the gap between the two Covishield shots.

According to official sources, the findings will soon be submitted to the Ministry of Health for further consideration of policymaking. “We have checked the data on a regular basis, but as the large amount of data for vaccinated people became available, we also investigated it. Any decision is made of these scientific facts. Will be driven by, “said Source.

“There is no doubt about reducing the gap, as the data show that the immune response improved with a 3-month gap between the two doses of Cobishield,” sources said.

Of the total dose of more than 112 chlores of the Covid vaccine given domestically so far, 88% is Covishield, a vaccine developed by Oxford University and Astra Zensea. The vaccine is manufactured locally by the Serum Institute of India. India is currently giving a second dose of Covishield with a 12-16 week gap. Over 79% of the eligible adult population is at least first vaccinated with Covid, while about 39% are fully vaccinated with two doses.

Approximately 1.2 billion people are delayed in the second vaccination, but the main reason for the delay in the second vaccination is also the long gap between the two jabs of Covishield, which accounts for the majority of vaccinations. ..

Currently, the majority of the eligible population is covered by the first dose of the vaccine and there is ample inventory, so some state and public health professionals are asking people to reduce the gap for increased protection. I am requesting the center. With two doses of Covishield.

However, the government argues that such a decision is driven by scientific recommendations from experts who evaluate it. Assessment of seroprevalence data also emphasizes the lack of an immediate need for booster immunization, rather complete vaccination is essential for long-term immunization, sources said. ET Health World